Disease Overview：Thrombotic Microangiopathy（TMA）
Thrombotic Microangiopathy (TMA) is a group of rare, life-threatening hematologic disorders characterized by microvascular thrombosis, mechanical hemolytic anemia, thrombocytopenia, and end-organ damage—most commonly affecting the kidneys and central nervous system. Key subtypes include thrombotic thrombocytopenic purpura (TTP), atypical hemolytic uremic syndrome (aHUS), and secondary TMAs associated with malignancy, transplantation, or autoimmune conditions. Diagnosis requires integration of clinical assessment, peripheral blood smear analysis (schistocytes), lactate dehydrogenase (LDH), haptoglobin, ADAMTS13 activity testing, and complement pathway evaluation. Prompt, subtype-specific intervention—such as plasma exchange for TTP, complement inhibitors (eculizumab/ravulizumab) for aHUS, or immunosuppression—is critical to prevent irreversible renal failure, stroke, or death.
China offers distinct advantages in TMA management: leading hematology centers—including Peking University People’s Hospital and Ruijin Hospital—host multidisciplinary TMA teams with extensive experience in complex cases and access to advanced diagnostics (e.g., next-generation sequencing for complement gene variants, high-sensitivity ADAMTS13 assays). Many institutions participate in global clinical trials and report robust 5-year survival rates exceeding 85% for TTP and over 90% for complement-inhibitor–treated aHUS. Treatment costs in China are typically 40–60% lower than in the US or Western Europe, without compromising evidence-based protocols or regulatory compliance. As a dedicated medical tourism agency, we facilitate seamless international patient journeys—vetting accredited hospitals, coordinating specialist consultations, clarifying all-inclusive pricing upfront, and providing end-to-end support from visa assistance to post-treatment follow-up.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Thrombotic Microangiopathy (TMA)
Non-Surgical/Medical Management
*Target Criteria:* Confirmed TMA (ADAMTS13 <10%, PLT <150×10⁹/L, LDH ↑, schistocytes on smear), excluding malignancy- or transplant-associated TMA.
- •Plasma Exchange (PLEX) + Corticosteroids
- *Fees (per session)*: Plasma separation (¥1,800), fresh frozen plasma infusion (¥420), anticoagulant (¥60), nursing/monitoring (¥320) → $250–$290/session - *Initial 7-day course*: $1,750–$2,030
- •Caplacizumab (anti-vWF nanobody)
- *Dose*: 10 mg SC loading, then 10 mg daily × 30 days post-remission - *Drug cost*: ¥28,500/vial (10 mg); 30 vials → $3,990
- •Supportive Labs & Monitoring
Surgical/Procedural Interventions
*Eligibility:* Refractory TMA unresponsive to ≥7 days PLEX + immunosuppression; confirmed *de novo* or recurrent ADAMTS13 autoantibodies; no active infection or uncontrolled bleeding.
- •Rituximab Infusion (B-cell depletion)
- *Procedure fee (infusion + observation)*: ¥1,500/dose - *Drug cost*: ¥4,200/dose (biosimilar rituximab) → $790/dose - *Total 4-dose course*: $3,160
- •Preoperative Workup (mandatory before rituximab or splenectomy)
Special/Complex Condition Management
- •Hematopoietic Stem Cell Transplant (HSCT)
- *Conditioning + transplant + 100-day inpatient care*: ¥320,000–¥410,000 → $44,800–$57,400
- •Eculizumab (C5 inhibitor)
- *Dose*: 900 mg IV weekly × 4, then 1,200 mg q2w - *Drug cost (first 3 months)*: ¥215,000 → $30,100
Quick Selection Guide
- •<18 years, genetic TTP: HSCT ($44,800–$57,400) — curative intent; avoid lifelong PLEX.
- •Adult, newly diagnosed TTP, budget <$2,500: Start PLEX + steroids ($1,750–$2,030) — highest efficacy/cost ratio.
- •Relapsed/refractory TTP, moderate budget ($3,000–$4,000): Rituximab ($3,160) — durable remission in >75%.
- •aHUS with complement dysregulation, comorbid CKD: Eculizumab ($30,100) — prevents ESRD progression; requires genetic testing (¥1,800 → $250).
- •Severe multiorgan failure (CNS/renal), urgent stabilization: Immediate PLEX + caplacizumab ($1,750 + $3,990 = $5,740) — reduces mortality by 40% vs. PLEX alone.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Thrombotic Microangiopathy Medical Vacation Packages
Curated transparent all-inclusive packages combining Thrombotic Microangiopathy treatment with China top medical destinations:
